Algernon Pharmaceuticals Targets Psychedelic Drug DMT for Stroke Program
Algernon Pharmaceuticals CEO, Christopher J. Moreau and CSO, Dr. Mark Williams with guest Dr. Mark Swaim join Cyndi Edwards, host of StreetSmart Live! as they discuss the company’s new Stroke Program. Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for ischemic stroke in humans and is planning to begin a clinical trial during 2021.
Be one of the first to hear why Algernon Pharmaceuticals chose psychedelic DMT for its new Stroke Program. Learn when Algernon Pharmaceuticals can begin DMT human clinical trials and hear what leading DMT and Stroke experts are saying.
